C5 Antibody (Monoclonal) , Biotinylated

A biotin conjugated murine monoclonal antibody to an epitope on C5.


Product Specifications

Citations1
Clonality

Monoclonal

Immnogen

Purified human protein.

Applications

See citations and technical data sheet for application info.

Concentration0.2 mg/mL
ConjugateBiotin
Cross Reactivity

Human, Baboon

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog NumberA705
Catalog Number (CE)N/A
Size250 µL
Price (USD)$365.00
Price (EURO)330,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

A biotin conjugated murine monoclonal antibody to an epitope on C5.

Size

250 µL

Concentration0.2 mg/mL
ApplicationsSee citations and technical data sheet for application info.
FormLiquid. Phosphate Buffered Saline (pH 7.0 ± 0.2), 1% Bovine Serum Albumin, with ≤ 0.1% Sodium Azide.
ClonalityMonoclonal
Immunogen

Purified human protein.

ConjugateBiotin
Cross ReactivityHuman, Baboon
Isotype

IgG1k

Purity

≥ 95% by SDS PAGE

SourceMouse
Specificity

This monoclonal antibody was raised against purified human C5. It is specific for an antigen expressed on the C5 but not on MAC Complex. This antibody inhibits the lysis of EA and will not bind to MAC bound to a membrane.

Storage

Short term (30 days) 4˚C. Long term at or below –20˚C.

Background

Complement protein, C5 is unique to the Terminal Complement Pathway. The C5 protein is composed of two subunits (Alpha – 115,000 kD and Beta – 75,000 kD) and is present in serum at a concentration of approximately 70 mg/L. Under normal conditions, activation of either the Classical, Lectin or Alternative Complement Pathways generates the C5 convertase which is capable of cleaving C5 into two fragments – C5a (a potent anaphylatoxin) and C5b. Together with other proteins of the Terminal Pathway, C5b forms the Membrane Attack Complex (MAC) or Terminal Complement Complex (TCC) at the surface of a target cell; resulting in cell lysis.

Citations

TitleYearApplicationsSample SpeciesSampleSample Details

Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients.

2021ELISAHuman

Plasma

N/A